Optum Infusion Services 308, LLC

Optum Infusion Services 308, LLC, a subsidiary of UnitedHealth Group Incorporated, delivers FDA 503A-compliant pharmaceutical compounding and hazardous chemotherapy preparation services to the Department of Veterans Affairs as a prime contractor on full-and-open, single-award indefinite-delivery contracts and blanket purchase agreements. The company operates from multiple locations including Chandler, Arizona; Houston, Texas; and Jackson, Mississippi, with no subcontract footprint in the federal space.

The company is concentrated entirely within the VA Veterans Health Administration across five Veterans Integrated Service Networks. VISN 16 (Texas and Mississippi operations) anchors the customer base with 7 awards worth $14.6 million combined potential value, followed by VISN 17 (Dallas and Amarillo, Texas) with 4 awards worth $7.9 million, and VISN 10 (Indiana, Ohio, and Michigan) with a single $7.6 million contract. VISN 2 (New Jersey and New York) and VISN 5 (West Virginia) round out the customer set with $2.6 million and $225 thousand respectively. All 16 awards in the source are prime contracts; the vendor holds no recorded subcontract positions.

Optum Infusion Services 308 operates across nine single-award indefinite-delivery contracts and one blanket purchase agreement, all issued without set-aside designation under firm fixed-price structures. Representative work includes a $7.6 million IDIQ with VISN 10 for hazardous chemotherapy compounding services across multiple VA medical centers in Indiana, Ohio, and Michigan (ultimate completion April 30, 2027); a $6 million IDIQ with VISN 17 for oncology drug pharmacy compounding at Dallas VA and Garland VA Clinic through October 31, 2030; a $3 million IDIQ with VISN 16 for FDA 503A pharmaceutical drug compounding at G.V. Montgomery VA Medical Center in Jackson, Mississippi through September 30, 2030; and a $500 thousand delivery order with VISN 16 for contingency medication compounding services under Executive Order 14398 at Michael E. DeBakey VA Medical Center in Houston through May 6, 2027. All contracts require next-day delivery capability, FDA 503A compliance, and adherence to USP 797, 795, and 800 standards for aseptic compounding of hazardous and non-hazardous pharmaceutical agents, IV tubing, and closed-system drug transfer devices.

Activity has grown sharply from a single award in 2021 and one in 2024 to eleven awards in 2025, with three additional awards through mid-2026. The combined potential value across all awards stands at $32.9 million, with $3.7 million obligated to date (11% of ceiling). Five awards totaling $2.3 million in combined potential value reach ultimate completion within the next twenty-four months, surfacing recompete exposure. The vendor's award portfolio concentrates in NAICS 325412 (Pharmaceutical Preparation Manufacturing) with 14 awards, and splits between PSC codes 4210 (Pharmacy Services) with 8 awards and 6540 (Drugs and Biologicals) with 7 awards. UnitedHealth Group's broader federal contracting presence, including a $3.3 billion Medical Disability Examination IDIQ with the VA, positions Optum Infusion Services 308 as part of a larger healthcare services footprint within the federal market, though this subsidiary operates independently as a prime contractor focused on specialized pharmaceutical compounding for cancer treatment programs and infusion therapy operations across VA facilities.